Chinese Authorities To Contain Number Of New Pharmaceutical Companies
This article was originally published in PharmAsia News
Executive Summary
In a recent proposal to expedite the restructuring of China's healthcare industry, the State FDA, the Ministry of Industry and Information Technology and the Ministry of Health have requested that the country's regional FDA offices raise technology requirements during drug review and approval to curb the number of new pharmaceutical companies